Drugs / SB218352_2AL
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00306995 | May 2005 → Jul 2006 | influenza | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB218352_2AL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00306995 ↗ |
| Modality | Vaccine | “Pandemic influenza A formulation 4 aluminium-adjuvanted vaccine” NCT00306995 ↗ |